📖

Progressive Bulbar Palsy (PBP)

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-progressive-bulbar-palsy

Related Entities

diseases-progressive-bulbar-palsy

Metadata

slug	diseases-progressive-bulbar-palsy
entity_type	disease
kg_node_id	None

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (83)

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%

related🧫Metabolic Pathway-Targeted Therapy in ALS60%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri60%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%

related🧫Brainstem Circuit Modulation for PSP60%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%

related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%

related🧫N-of-1 Clinical Trial Design for CBS/PSP60%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%

related🧫Progranulin Replacement Therapy for FTD — Vector Development60%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%

related🧫PSP and CBS Biomarker Validation Study60%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%

related🧫TDP-43 PET Ligand Development for FTD and ALS60%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%

mentions🧫Metabolic Pathway-Targeted Therapy in ALS55%

mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker55%

mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk55%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri55%

mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring55%

mentions🧫Brainstem Circuit Modulation for PSP55%

mentions🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT55%

mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study55%

mentions🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio55%

mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design55%

mentions🧫N-of-1 Clinical Trial Design for CBS/PSP55%

mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers55%

mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic55%

mentions🧫Progranulin Replacement Therapy for FTD — Vector Development55%

mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD55%

mentions🧫PSP and CBS Biomarker Validation Study55%

mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen55%

mentions🧫TDP-43 PET Ligand Development for FTD and ALS55%

mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des55%

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%

related🧫Metabolic Pathway-Targeted Therapy in ALS54%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri54%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%

related🧫Brainstem Circuit Modulation for PSP54%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%

related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design54%

related🧫N-of-1 Clinical Trial Design for CBS/PSP54%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%

related🧫Progranulin Replacement Therapy for FTD — Vector Development54%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%

related🧫PSP and CBS Biomarker Validation Study54%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%

related🧫TDP-43 PET Ligand Development for FTD and ALS54%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%

mentions🧪Cryptic Exon Silencing Restoration50%

mentions🧪Glycine-Rich Domain Competitive Inhibition50%

mentions🧪Cross-Seeding Prevention Strategy50%

mentions🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying protein aggregation cross50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬How does metabolic reprogramming (glucose metabolism shifts,50%

mentions🧫s:** - Single-cell RNA-seq to measure editing efficiency acr44%

mentions🧫ALS Regional Onset and Spread: Network-Level Staging Model44%

mentions🧫Environmental Exposure Causal Attribution in ALS — Experimen44%

mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa40%

mentions🔬What are the mechanisms underlying protein aggregation cross40%

mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%

related🧪Cryptic Exon Silencing Restoration40%

related🧪Glycine-Rich Domain Competitive Inhibition40%

related🧪Cross-Seeding Prevention Strategy40%